In AML, molecular MRD monitoring includes quantification of PML-RARA(25, 26), RUNX1-RUNX1T1(27), CBFB-MYH11(28), and mutated-NPM1 (29, 30). This evidence concerns the gene RARA and acute myeloid leukemia.